🦴 Secondary Hyperparathyroidism and CKD
Understanding PTH, calcium, phosphate and vitamin D across CKD stages - guided by the KDIGO 2017 CKD-MBD guideline
Quick Reference
Practical starting points based on the KDIGO 2017 CKD-MBD guideline. Every row can change based on individual lab trends, CKD stage and dialysis status - see the sections below.
| Component | Practical Recommendation |
|---|---|
| Serum phosphate | Lower toward normal only when progressively rising or persistently elevated - not restricted pre-emptively while phosphate is normal. |
| Dietary phosphate | Prioritize cutting phosphate additives in processed food and drinks first; natural (organic) phosphorus in whole foods is less completely absorbed. |
| Phosphate binders | Reserved for elevated phosphate, not used pre-emptively; dose of calcium-based binders should be limited. |
| Serum calcium | Usually total calcium (not routinely albumin-corrected). Avoid hypercalcemia. Mild, asymptomatic hypocalcemia may be tolerated rather than aggressively corrected. |
| PTH (CKD G3a-G5, not on dialysis) | No fixed normal target. Evaluate modifiable factors (phosphate intake, hyperphosphatemia, hypocalcemia, vitamin D) if PTH is progressively rising or persistently above the upper limit of normal. |
| Vitamin D - nutritional (25(OH)D) | May be measured, with repeat testing individualized rather than fixed; correct deficiency/insufficiency using the same strategies recommended for the general population. |
| Vitamin D - active (calcitriol/analogs) | Not used routinely in non-dialysis CKD. Reserved for CKD G4-G5 with severe, progressive hyperparathyroidism. |
| Dialysis (CKD G5D) PTH-lowering therapy | Calcimimetic, calcitriol, or a vitamin D analog, or a combination - all are acceptable options, chosen individually. |
| Severe, refractory hyperparathyroidism | Parathyroidectomy is considered when medical and pharmacological therapy has failed. |
⚠️ IMPORTANT - Don't Self-Adjust Calcium, Vitamin D or Calcimimetic Therapy
Starting, stopping or increasing calcium supplements, vitamin D, or calcimimetic medication on your own can cause hypercalcemia, hypocalcemia, or dangerous swings in PTH. These medications are typically adjusted based on lab trends specific to each person, not a fixed dose that applies to everyone.
1. What Is Secondary Hyperparathyroidism in CKD?
As kidney function declines, the kidneys become less able to excrete phosphate and less able to activate vitamin D into its hormonally active form, calcitriol. Phosphate retention and reduced calcitriol both tend to lower blood calcium and directly stimulate the parathyroid glands, while a hormone called FGF-23 rises early in CKD to help the kidneys excrete more phosphate - but this comes at the cost of further suppressing calcitriol production.
The parathyroid glands respond to these signals by releasing more parathyroid hormone (PTH), which raises blood calcium by pulling it from bone, increasing calcium reabsorption in the kidney, and stimulating calcitriol production. If this stimulation continues for a long time, as it does throughout progressive CKD, the parathyroid glands can enlarge (hyperplasia) and gradually become less responsive to the usual feedback signals. This chronic, kidney-disease-driven overactivity is called secondary hyperparathyroidism (SHPT) - "secondary" because it's a response to the underlying kidney disease, not a primary problem of the parathyroid glands themselves.
With prolonged, severe stimulation, nodular parathyroid hyperplasia can become increasingly autonomous. True autonomous PTH secretion - no longer suppressed by the usual calcium feedback and often accompanied by hypercalcemia - is generally termed tertiary hyperparathyroidism, a distinct stage from secondary hyperparathyroidism that most often develops after years of poorly controlled SHPT.
Persistent, severe SHPT contributes to abnormal bone turnover and renal osteodystrophy (a spectrum of bone disease seen in CKD, including high-turnover and low-turnover disease). Broader CKD-MBD abnormalities - disordered PTH, calcium and phosphate metabolism together - are also associated with fracture, vascular calcification, cardiovascular events and mortality, though this relationship is complex and not fully explained by a simple cause-and-effect chain. The EVOLVE trial, discussed in Section 6, is a good example: lowering PTH with cinacalcet did not clearly reduce cardiovascular events in its primary analysis, even though PTH itself dropped substantially.
SHPT is usually silent in its early stages and is identified through blood tests - calcium, phosphate, PTH and vitamin D - often before any symptoms appear. This is why periodic monitoring matters more than waiting for symptoms.
2. Diagnosis and Monitoring: Trends Matter More Than a Single Number
The KDIGO 2017 update made an explicit, deliberate shift: treatment decisions in CKD-MBD should be based on serial trends in phosphate, calcium and PTH considered together, rather than reacting to one abnormal result in isolation.
PTH assays also vary meaningfully between laboratories and platforms, which is part of why KDIGO has not set a single universal "normal" PTH target for non-dialysis CKD - the optimal level for a given person is genuinely not known, and a value that looks high on paper may simply reflect a stable, adaptive response to reduced kidney function rather than a problem requiring treatment.
Labs Typically Monitored
- Serum calcium - usually total calcium
- Serum phosphate
- Intact PTH (iPTH)
- 25-hydroxyvitamin D (25(OH)D, sometimes called calcidiol)
- Alkaline phosphatase (a marker that can reflect bone turnover)
A Note on "Corrected" Calcium
Total calcium is the standard measurement; ionized calcium can be considered when an accurate assessment of biologically active calcium is clinically important, such as in advanced CKD or when albumin is markedly abnormal. A 2026 position statement from the Joint IOF Working Group, IFCC Committee on Bone Metabolism, and EFLM Committee on CKD concluded that albumin-adjustment ("corrected" calcium) formulas should no longer be routinely reported, since they can misclassify calcium status - particularly in advanced CKD and hypoalbuminemia - compared with total or ionized calcium.
Bone Density Scanning and Bone Biopsy
DXA bone density scanning is reasonable in CKD when the result would actually change treatment decisions - not as a routine, automatic test for everyone. Bone biopsy remains the definitive way to characterize the specific type of renal bone disease, but like DXA, it's considered when the result will influence what treatment is chosen, rather than being performed routinely.
3. Phosphate: Treat the Trend, Not a Single Test
Phosphate binders should generally not be started pre-emptively when serum phosphate is normal - KDIGO 2017 suggests using them to lower phosphate toward the normal range in CKD G3a through G5D only once phosphate is progressively rising or persistently elevated. Dietary phosphate modification is primarily used the same way, for elevated phosphate - but there's an important nuance: even when phosphate is still normal, if PTH itself is progressively rising or persistently above the upper limit of normal, KDIGO specifically lists high phosphate intake as one of the modifiable factors that should be evaluated, alongside hypocalcemia and vitamin D deficiency.
This distinction matters in practice. Trials that tested phosphate binders in people with CKD G3-G4 and normal or near-normal phosphate found that while binders lowered phosphate and reduced phosphate excretion, they also increased calcium balance and, in one trial, arterial calcification scores - without a clear benefit. That's why binders aren't started pre-emptively. But someone can have a rising PTH with phosphate that's still technically "normal," driven by a diet heavy in phosphate additives - in that situation, reducing phosphate intake (particularly highly absorbable additives) is a reasonable step even though binders wouldn't yet be indicated.
3.1. Diet and Phosphate Source Matter
Not all dietary phosphorus behaves the same way in the body. KDIGO specifically recommends considering the source of phosphate - animal, vegetable, or additive - when making dietary recommendations, because bioavailability differs substantially. These figures are approximate; actual absorption varies by the specific phosphate compound, the food matrix, and how the food is prepared:
- Additive (inorganic) phosphate - found in many processed foods, colas and packaged products - is absorbed almost completely (roughly 90-100%) and is the highest-yield target for reduction.
- Organic phosphate in animal protein (meat, fish, poultry, eggs, dairy) is absorbed at a moderate rate (roughly 40-60%).
- Organic phosphate in plant foods (legumes, whole grains, nuts, seeds) is bound to phytate, which meaningfully limits its absorption (roughly 20-50%).
3.2. Phosphate Binders
Phosphate binders are reserved for people with elevated phosphate, not used as a preventive measure. When binders are needed, KDIGO 2017 suggests restricting the dose of calcium-based binders, reflecting concern that regular calcium-based binder use can contribute to a positive calcium balance and vascular calcification, especially when combined with active vitamin D therapy. Non-calcium-based binders (such as sevelamer or lanthanum) may be favored when additional calcium loading is undesirable - for example with hypercalcemia, vascular calcification, or low PTH/adynamic bone disease - but KDIGO does not designate any single binder class as universally preferred for every patient; calcium-based binders still have a legitimate role, particularly where cost is a major constraint. Binders are typically most effective when taken together with meals, since they work by binding phosphate within food in the gut.
3.3. Don't Cut Protein to Control Phosphate
Protein-rich foods are also often the foods highest in phosphate, which makes it tempting to control phosphate simply by eating less protein overall. That's the wrong lever to pull. Adequate protein remains essential throughout CKD - roughly 0.6-0.8 g/kg/day is a reasonable, individualized range for metabolically stable adults with CKD G3-G5 not on dialysis, rising to about 1.0-1.2 g/kg/day once dialysis begins to prevent protein-energy wasting. Rather than reducing protein quantity, the more effective approach is choosing protein sources with a more favorable protein-to-phosphate ratio - fresh fish, poultry, egg whites and lean meat generally offer more protein per unit of phosphate than processed meat, organ meats, or excessive dairy - and cutting phosphate additives, which contribute little or no protein at all. Restricting protein to chase a phosphate or PTH number is a common and avoidable route to malnutrition (see Section 9).
4. Calcium: Avoiding Both Extremes
KDIGO 2017 suggests avoiding hypercalcemia in adults with CKD G3a-G5D - a shift from the earlier, more rigid instruction to keep calcium within the normal range at all times.
Mild, asymptomatic hypocalcemia is now considered acceptable to tolerate in some situations - for example, during calcimimetic therapy, which lowers calcium as part of how it works - rather than automatically correcting it, since over-correction with calcium supplements or active vitamin D carries its own risk of harm.
As noted above, the dose of calcium-based phosphate binders should be limited (KDIGO 2017, graded recommendation) because regular use can push total calcium intake - from diet, supplements and binders combined - toward a positive calcium balance, which has been linked to vascular and soft-tissue calcification.
Dialysate Calcium
For people on hemodialysis (CKD G5D), KDIGO suggests a dialysate calcium concentration of 1.25-1.5 mmol/L (2.5-3.0 mEq/L), with flexibility to individualize based on a person's calcium status and concurrent medications.
Calcium From Food
Dairy products, fortified plant milks, calcium-set tofu, small fish eaten with soft bones, and leafy greens are common calcium sources. These don't need blanket avoidance, but the right amount is genuinely individual - it depends on current calcium and phosphate levels, whether calcium-based binders or active vitamin D are being used, and dialysis status. Calcium supplements should not be started or adjusted without medical guidance.
5. Vitamin D: Two Different Things That Are Easily Confused
"Vitamin D" in CKD-MBD actually refers to two distinct categories of treatment with very different roles - mixing them up is one of the most common sources of confusion for patients.
5.1. Nutritional Vitamin D (25(OH)D / Calcidiol)
This is the same vitamin D measured and treated in the general population - made in skin from sun exposure, obtained from food, or taken as a standard cholecalciferol (D3) or ergocalciferol (D2) supplement. KDIGO suggests that 25(OH)D levels may be measured, with repeat testing individualized according to the baseline value and any therapeutic interventions rather than on a fixed schedule, and that deficiency or insufficiency be corrected using the same treatment strategies recommended for the general population. This recommendation is unchanged since 2009 and applies across all CKD stages, independent of PTH or phosphate status.
5.2. Active Vitamin D (Calcitriol, Alfacalcidol, Paricalcitol and Similar Analogs)
These are the hormonally active or near-active forms of vitamin D, used specifically to suppress PTH secretion - kidneys with reduced function can't reliably make enough of this active form on their own. KDIGO 2017 suggests that calcitriol and vitamin D analogs not be used routinely in adults with CKD G3a-G5 who are not on dialysis. This reflects results from two major randomized trials (PRIMO and OPERA) in which paricalcitol lowered PTH but did not improve heart structure or function, while significantly increasing the frequency of hypercalcemia compared with placebo. Instead, active vitamin D is reserved for CKD G4-G5 with severe and progressive hyperparathyroidism, generally starting at a low dose and monitoring closely to avoid hypercalcemia.
Common dietary and lifestyle sources:
- Safe sun exposure, as appropriate for the individual and local guidance
- Fatty fish (salmon, mackerel, sardines)
- Egg yolk
- Vitamin D-fortified dairy or plant milk
- Mushrooms exposed to UV light
- Standard-dose over-the-counter or prescribed cholecalciferol/ergocalciferol supplements, as advised by the care team
5.3. In Dialysis (CKD G5D)
For people who require PTH-lowering therapy on dialysis, calcitriol or a vitamin D analog is one of several acceptable options alongside calcimimetics - see the next section. No single option has been shown to be clearly superior to the others; the right choice depends on each person's calcium and phosphate levels and other therapies they're already taking.
6. Calcimimetics: Cinacalcet, Etelcalcetide and PTH-Lowering Therapy on Dialysis
Calcimimetics work differently from vitamin D therapy: rather than acting through the vitamin D pathway, they increase the sensitivity of the parathyroid gland's calcium-sensing receptor, so the gland reads blood calcium as "higher" than it actually is and reduces PTH secretion accordingly. Because of this mechanism, calcimimetics tend to lower blood calcium - the opposite direction of risk compared with calcitriol and vitamin D analogs, which tend to raise it.
Dialysis-Stage Therapy
For adults with CKD G5D requiring PTH-lowering therapy, KDIGO 2017 suggests a calcimimetic, calcitriol, or a vitamin D analog, or a combination of a calcimimetic with calcitriol or a vitamin D analog. All of these are considered acceptable first-line options - there is no evidence that any single one is clearly superior, and the choice is guided by a person's calcium and phosphate levels and other concurrent therapies.
Context: The EVOLVE Trial
A large randomized trial (EVOLVE) tested cinacalcet against placebo for cardiovascular outcomes in dialysis patients and did not meet its primary endpoint in the main analysis. Pre-specified analyses that adjusted for factors like age suggested a possible cardiovascular benefit, but this remains an area of genuine clinical uncertainty rather than settled evidence - which is part of why KDIGO frames calcimimetics as one acceptable option among several, not a clearly superior one.
Calcimimetics are not a routine treatment for people with CKD who are not on dialysis; their evidence base and typical use are centered on dialysis-dependent secondary hyperparathyroidism.
7. Parathyroidectomy: When Medical Therapy Isn't Enough
For adults with CKD G3a-G5D who have severe hyperparathyroidism that fails to respond to medical and pharmacological therapy, KDIGO 2017 suggests parathyroidectomy - surgical removal of some or most of the parathyroid tissue. This is a conditional recommendation (graded 2B in KDIGO's system, meaning "we suggest" rather than "we recommend") that has remained essentially unchanged since the original 2009 guideline; it reflects the same weak-to-moderate strength of evidence as most other recommendations in this area, not an unusually strong one.
Hungry Bone Syndrome After Surgery
After parathyroidectomy, calcium, phosphate and magnesium can drop rapidly as bone - which had been losing mineral under prolonged high PTH exposure - suddenly starts rebuilding and pulling these minerals out of the bloodstream. This is called hungry bone syndrome and requires close monitoring and calcium and vitamin D repletion in the days and weeks after surgery.
8. Practical Food Guidance by CKD Stage
Diet is one of the few parts of CKD-MBD management a person controls day to day, alongside medication and lab monitoring - but how much dietary attention phosphate actually needs depends heavily on CKD stage and current lab values, not on the diagnosis of CKD by itself. The table below is a general starting point, not a fixed prescription.
At a Glance: What to Eat and Drink
Generally Safe to Enjoy (Ordinary Portions, Normal Labs)
- Fresh fruits and vegetables
- Fresh fish, poultry, lean meat and eggs, including egg whites, in ordinary portions
- Water, plain coffee and tea without additives
- Home-cooked whole grains, legumes and dairy or fortified plant milk in ordinary portions
- Herbs, spices and freshly prepared meals made without phosphate additives
Limit or Avoid First (Especially Once Phosphate or PTH Is Elevated)
- Dark colas and other phosphoric-acid-containing sodas
- Processed, cured or smoked meats, sausages and deli meats
- Processed cheese products
- Instant noodles, ready meals, fast food and other heavily packaged foods
- Any ingredient label listing "phosphate," "phosphoric acid" or "polyphosphate"
This quick list applies mainly once phosphate or PTH is actually elevated - it is not a reason to cut protein-rich whole foods like meat, fish, dairy, eggs, legumes or nuts when labs are normal (see Section 3.3). The stage-by-stage guide and detailed table below explain how this shifts as CKD progresses.
CKD G1-G2, Normal Labs
No special phosphate, calcium or PTH restriction is typically needed. A generally balanced diet is appropriate, and nutritional vitamin D should be treated the same as it would be for anyone else.
CKD G3a-G3b, Labs Still Normal
Routine monitoring continues, but reflexive restriction isn't necessary. Limiting ultra-processed, phosphate-additive-heavy foods and drinks is a reasonable general habit at this stage, more for overall diet quality than because of a proven phosphate-specific need.
CKD G4-G5, Not on Dialysis, With Hyperphosphatemia or Progressive/Persistent PTH Elevation
If PTH is rising despite normal serum phosphate, the first step is assessment, not restriction: check vitamin D status, calcium, and how much phosphate - especially highly bioavailable additives from packaged food and dark sodas - is actually being consumed, rather than automatically imposing a low-phosphorus diet. Once phosphate itself is elevated, dietary attention becomes more clearly useful: prioritize cutting phosphate additives first, moderate portions of very high-phosphate animal foods (particularly organ meats and processed meat/cheese), and preserve adequate protein intake by favoring sources with a more favorable protein-to-phosphate ratio, such as egg whites and fresh fish or poultry in appropriate portions (see Section 3.3).
CKD G5D (Dialysis)
Dietary phosphate restriction remains an important part of management alongside phosphate binders, since dialysis alone typically removes only a limited amount of phosphate. Protein needs are actually higher at this stage (roughly 1.0-1.2 g/kg/day) to prevent protein-energy wasting, so the practical goal is balancing adequate protein with phosphate control through food choice and binder timing - not simply restricting protein.
Food Categories: Caution vs. Generally Fine
| Food Category | Use Caution / Limit First (especially once phosphate or PTH is elevated) | Generally Fine in Ordinary Portions (when labs are normal) |
|---|---|---|
| Processed & packaged foods | Ingredient labels listing "phosphate," "phosphoric acid" or "polyphosphate"; deli meats, sausages, cured/smoked meats, processed cheese, instant noodles, ready meals | Freshly prepared foods made from whole ingredients without phosphate additives |
| Beverages | Dark colas and other phosphoric-acid-containing sodas; some bottled iced teas and energy drinks with phosphate additives | Water, plain coffee or tea, and milk in a portion that fits the individual's calcium/phosphate plan |
| Meat, poultry, fish & eggs | Organ meats (liver, kidney), processed or cured meat, and very large portions of any protein once phosphate is elevated | Fresh chicken, fish, lean meat and egg whites in appropriate portions - a more favorable protein-to-phosphate ratio than processed alternatives |
| Dairy & plant alternatives | Large or frequent portions of milk, cheese and processed cheese products once phosphate is elevated | A moderate, individualized portion of dairy or fortified plant milk - a useful calcium and vitamin D source that doesn't need blanket avoidance when labs are normal |
| Legumes, whole grains & nuts | Very large portions once phosphate or PTH is elevated, since these contain moderate organic phosphate alongside valuable protein and fiber | Normal culinary portions in earlier CKD stages or when phosphate is normal - the organic phosphate they contain is less completely absorbed than additive phosphate |
| Bakery & fast food | Packaged baked goods with phosphate-based leavening or preservatives, fast food, and instant or ready-to-eat meals | Home-prepared bread, rice and starches made without phosphate additives |
These caution/fine distinctions apply mainly once phosphate or PTH is actually elevated. In earlier CKD stages with normal labs, most of the "caution" foods can still be eaten in ordinary portions as part of a balanced diet.
9. Avoiding Over-Restriction and Malnutrition
Because phosphorus, protein and calcium overlap so heavily in everyday foods, it's easy to over-restrict diet in CKD-MBD out of caution - cutting dairy, eggs, legumes, nuts and adequate protein even when labs don't call for it. This carries real risk, particularly for:
- Older adults
- CKD stage G4-G5
- People already eating poorly for any reason
- People with sarcopenia (low muscle mass and strength)
- People on dialysis, whose protein needs are actually higher, not lower
Dietary changes for CKD-MBD should be proportional to the actual lab trend and CKD stage, reassessed regularly, and ideally guided by a renal dietitian who can individualize recommendations rather than applying a blanket restriction to everyone with CKD.
10. Common Mistakes to Avoid
Restricting phosphorus-containing whole foods when labs are normal
Cutting dairy, eggs, legumes, nuts and whole grains by default - rather than in response to an actual elevated phosphate - removes valuable protein, calcium and nutrients without a proven benefit.
Chasing a single PTH number instead of the trend
Reacting to one elevated PTH result, or trying to force PTH down to the same "normal" range used for the general population, ignores that the optimal PTH level in non-dialysis CKD is genuinely unknown and that modifiable factors should be evaluated first.
Self-adjusting calcium, vitamin D or calcimimetic therapy
Starting, stopping or changing the dose of these medications without guidance can push calcium too high or too low, since calcimimetics and active vitamin D affect calcium in opposite directions.
Overlooking phosphate additives while focusing only on "high-phosphorus" whole foods
Additive phosphate in processed food and dark sodas is absorbed far more completely than the organic phosphate in dairy, legumes or nuts, so it's usually the more effective first target.
Conclusion
Secondary hyperparathyroidism in CKD is best managed through individualized, trend-based decisions rather than reflexive restriction or chasing a single lab value.
Phosphate-lowering treatment - whether diet or binders - is reserved for phosphate that is elevated or rising, not applied pre-emptively. Calcium should stay out of the hypercalcemic range while mild, asymptomatic hypocalcemia is often tolerated. Nutritional vitamin D deficiency should be corrected the same way it would be for anyone else, while active vitamin D and calcimimetics are reserved for more specific, more severe situations and require individualized dosing.
For diet specifically: prioritize cutting phosphate additives in processed food first, don't reflexively restrict whole foods like dairy, eggs, legumes and nuts when labs are normal, and keep protein intake adequate - especially on dialysis, where needs actually increase.
📚 References
⚠️ Disclaimer
Information on this page is for educational and reference purposes only and does not replace professional medical or dietetic advice. Phosphate, calcium, PTH and vitamin D management must be individualized based on CKD stage, dialysis status, lab trends, medications and bone health. Please consult your nephrologist or registered dietitian before starting, stopping or changing any calcium, vitamin D, phosphate binder or calcimimetic therapy, or before making significant changes to your diet.